Zevra Therapeutics (ZVRA) Total Current Liabilities (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Total Current Liabilities came in at $47.0 million in Q1 2026, up 74.33% YoY from $27.0 million in Q1 2025, and up 19.73% on a QoQ basis from $39.3 million in Q4 2025.
Zevra Therapeutics (ZVRA) Total Current Liabilities (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Total Current Liabilities data on file, last reported at $47.0 million in Q1 2026.
- Quarterly Total Current Liabilities rose 74.33% year-over-year to $47.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.0 million (up 74.33% YoY) and the FY2025 annual result came in at $39.3 million, up 15.3% from the prior year.
- Total Current Liabilities climbed to $47.0 million in Q1 2026, from $39.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $73.7 million in Q4 2023 to a low of $7.2 million in Q2 2022.
- A 5-year average of $29.1 million and a median of $28.8 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities surged 513.16% — and 2024, when it tumbled 53.79%.
- Tracing ZVRA's Total Current Liabilities over 5 years: stood at $12.0 million in 2022, then surged by 513.16% to $73.7 million in 2023, then plunged by 53.79% to $34.1 million in 2024, then grew by 15.3% to $39.3 million in 2025, then advanced by 19.73% to $47.0 million in 2026.
- The last three Total Current Liabilities figures came in at $47.0 million (Q1 2026), $39.3 million (Q4 2025), and $26.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 48.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.63 Mn |
| Mar 31, 2026 | 47.03 Mn |
| Dec 31, 2025 | 39.28 Mn |
| Sep 30, 2025 | 26.11 Mn |
| Jun 30, 2025 | 28.83 Mn |
| Mar 31, 2025 | 26.98 Mn |
| Dec 31, 2024 | 34.07 Mn |
| Sep 30, 2024 | 34.48 Mn |
| Jun 30, 2024 | 30.45 Mn |
| Mar 31, 2024 | 29.91 Mn |
| Dec 31, 2023 | 73.72 Mn |
| Sep 30, 2023 | 21.71 Mn |
| Mar 31, 2023 | 16.01 Mn |
| Dec 31, 2022 | 12.02 Mn |
| Sep 30, 2022 | 8.60 Mn |
| Jun 30, 2022 | 7.21 Mn |
| Dec 31, 2021 | 4.23 Mn |
| Sep 30, 2021 | 3.70 Mn |
| Jun 30, 2021 | 5.96 Mn |
| Mar 31, 2021 | 4.24 Mn |